Renaissance Technologies's ABCL Position Overview
Renaissance Technologies (via Renaissance Technologies LLC) currently holds 2.39 M shares of AbCellera Biologics Inc. (ABCL) worth $8.17 M, representing 0.01% of the portfolio. First purchased in 2021-Q2, this medium-term investment has been held for 19 quarters.
Based on 13F filings, Renaissance Technologies has maintained a strategic position in ABCL, demonstrating sustained confidence in this investment. Largest addition occurred in Q1 2022, adding 2.08 M shares. Largest reduction occurred in Q3 2022, reducing 1.06 M shares.
Analysis based on 13F filings available since 2013 Q2
Renaissance Technologies's AbCellera Biologics (ABCL) Holding Value Over Time
Track share changes against reported price movement
Quarterly AbCellera Biologics (ABCL) Trades by Renaissance Technologies
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2021 | +403,200 | New Buy | 403,200 | $22.00 |
| Q3 2021 | -318,900 | Reduce 79.09% | 84,300 | $20.04 |
| Q4 2021 | +454,903 | Add 539.62% | 539,203 | $14.30 |
| Q1 2022 | +2.08 M | Add 385.46% | 2.62 M | $9.75 |
| Q2 2022 | +1.42 M | Add 54.20% | 4.04 M | $10.65 |
| Q3 2022 | -1.06 M | Reduce 26.15% | 2.98 M | $9.89 |
| Q4 2022 | -858,400 | Reduce 28.80% | 2.12 M | $0.01 |
| Q1 2023 | +689,100 | Add 32.47% | 2.81 M | $0.01 |
| Q2 2023 | -274,900 | Reduce 9.78% | 2.54 M | $0.01 |
| Q3 2023 | -844,550 | Reduce 33.29% | 1.69 M | $4.60 |
| Q4 2023 | -232,550 | Reduce 13.74% | 1.46 M | $5.71 |
| Q1 2024 | +30,100 | Add 2.06% | 1.49 M | $4.53 |
| Q2 2024 | +239,000 | Add 16.04% | 1.73 M | $2.96 |
| Q3 2024 | +1.22 M | Add 70.47% | 2.95 M | $2.60 |
| Q4 2024 | -459,810 | Reduce 15.60% | 2.49 M | $2.93 |
| Q1 2025 | +407,136 | Add 16.37% | 2.89 M | $2.23 |
| Q2 2025 | +413,400 | Add 14.28% | 3.31 M | $3.43 |
| Q3 2025 | +53,300 | Add 1.61% | 3.36 M | $5.03 |
| Q4 2025 | -971,500 | Reduce 28.91% | 2.39 M | $3.42 |
Renaissance Technologies's AbCellera Biologics Investment FAQs
Renaissance Technologies first purchased AbCellera Biologics Inc. (ABCL) in Q2 2021, acquiring 403,200 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies has held AbCellera Biologics Inc. (ABCL) for 19 quarters since Q2 2021.
Renaissance Technologies's largest addition to AbCellera Biologics Inc. (ABCL) was in Q1 2022, adding 2,617,603 shares worth $25.52 M.
According to the latest 13F filing for Q4 2025, Renaissance Technologies's firm, Renaissance Technologies LLC, owns 2,389,229 shares of AbCellera Biologics Inc. (ABCL), valued at approximately $8.17 M.
As of the Q4 2025 filing, AbCellera Biologics Inc. (ABCL) represents approximately 0.01% of Renaissance Technologies's publicly disclosed stock portfolio, making it one of their key holdings.
Renaissance Technologies's peak holding in AbCellera Biologics Inc. (ABCL) was 4,036,303 shares, as reported at the end of Q2 2022.